IDEAYA Biosciences Scheduled, Nasdaq: IDYA

Phase 1 biotech developing targeted therapies for genetically-defined cancers.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality - which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response. Our most advanced product candidate is IDE196, a protein kinase C, or PKC, inhibitor for genetically-defined cancers having g protein subunit alpha q, or GNAQ, or g protein subunit alpha 11, or GNA11, gene mutations. We obtained an exclusive, worldwide license to IDE196 from Novartis.
more less
IPO News for IDEAYA Biosciences
more
IPO Data
IPO File Date 04/26/2019
Offer Price
Price Range $13.00 - $15.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $13.00 - $15.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2015
Employees 56
Website www.ideayabio.com